Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. CbdMD, Inc.
  6. News
  7. Summary
    YCBD   US12482W1018


Delayed Quote. Delayed Nyse - 09/20 04:10:00 pm
1.94 USD   -1.52%
09/18CBDMD : What is Full Spectrum CBD?...
09/16CBDMD, INC. : Other Events (form 8-K)
09/16CBD FOR DOGS : Is CBD Safe for Dogs?...
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CbdMD, Inc. Appoints John J. Wiesehan III as Chief Revenue Officer

07/27/2021 | 09:24am EDT

On July 22, 2021 (the “Closing”), cbdMD, Inc.; Twenty Two Capital, LLC; Vieo Design, LLC; John J. Wiesehan III; and Bradley D. Trawick entered into an Asset Purchase Agreement. Under the Asset Purchase Agreement, the Company acquired from the Seller the CBD online marketplace, DirectCBDOnline.com, related trademarks, inventory, certain other assets, and assumed certain liabilities. The DirectCBDOnline.com website provides CBD education and information and a selection of the highest-quality CBD products, including, but not limited to, oils, tinctures, salves, capsules, and gummies. On July 22, 2021, pursuant to the Closing of the Asset Purchase Agreement Mr. John J. Wiesehan III was appointed Chief Revenue Officer of the Company. Mr. Wiesehan provided consulting services to the Company from June 2021 through the Closing. Mr. Wiesehan, age 37, founded Twenty Two in 2018 and has served as its chief executive officer since its inception. From September 2012 to October 2017 he served as vice president of sales for Ballantyne Brands LLC, a manufacturer of ENDS (non combustible tobacco) products. He is a graduate of Appalachian State University. The Company and Mr. Wiesehan entered into a two year employment agreement effective on the Closing. Under the terms of the employment agreement, the Company agreed to pay him an initial annual base salary of $180,000 and he is entitled to a discretionary bonus up to 40% of his base salary at the sole determination of the Compensation Committee of the Company’s board of directors. He will also be eligible for a one time cash performance bonus of $160,000 payable in cash upon the Company reporting total net sales (as defined under the employment agreement) equal or exceeding $16,000,000 for any fiscal quarterly period prior to September 30, 2022. In addition, he is entitled to participate in benefit programs the Company offers its employees and paid vacation. The employment agreement may be terminated by the Company in the event of his death or disability, by the company for cause (as defined in the employment agreement), or by either party without cause. The agreement contains customary confidentiality, non-compete, and indemnification provisions.

ę S&P Capital IQ 2021
All news about CBDMD, INC.
09/18CBDMD : What is Full Spectrum CBD?...
09/16CBDMD, INC. : Other Events (form 8-K)
09/16CBD FOR DOGS : Is CBD Safe for Dogs?...
09/15CBDMD : CBD for Sleep – Tinctures vs Softgels...
09/13CBDMD : Signs 2021 CrossFit Champion Justin Medeiros and Two-Time CrossFit Champ..
09/10CBDMD : 8 Hemp Gummies Benefits...
09/09CBDMD : Where to Buy CBD Oil...
09/07CBDMD : Debuts New Line of CBD Infused Drink Mixes
09/07CbdMD Debuts New Line of CBD Infused Drink Mixes
09/02CBDMD : How Long Does it Take for Hemp Gummies to Work?...
More news
Analyst Recommendations on CBDMD, INC.
More recommendations
Financials (USD)
Sales 2021 45,9 M - -
Net income 2021 -23,4 M - -
Net Debt 2021 33,0 M - -
P/E ratio 2021 -5,24x
Yield 2021 -
Capitalization 114 M 114 M -
EV / Sales 2021 3,20x
EV / Sales 2022 2,64x
Nbr of Employees 165
Free-Float 63,6%
Duration : Period :
cbdMD, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CBDMD, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,94 $
Average target price 3,70 $
Spread / Average Target 90,7%
EPS Revisions
Managers and Directors
Martin A. Sumichrast Chairman & Co-Chief Executive Officer
Raymond Scott Coffman President, Co-Chief Executive Officer & Director
T. Ronan Kennedy Chief Operating & Financial Officer
Sibyl Swift Vice President-Scientific & Regulatory Affairs
Bakari Sellers Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CBDMD, INC.-33.22%114
JOHNSON & JOHNSON4.09%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556